Shares of Kadmon Holdings, Inc. (NYSE:KDMN) have been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $9.75.

Several equities research analysts recently commented on KDMN shares. WBB Securities cut Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price for the company. in a research note on Monday, October 9th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a research note on Friday, November 17th. Finally, Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a research note on Tuesday, November 21st.

A number of institutional investors have recently made changes to their positions in KDMN. Susquehanna International Group LLP lifted its holdings in shares of Kadmon by 3,211.2% in the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after purchasing an additional 429,752 shares in the last quarter. Crestline Management LP bought a new position in shares of Kadmon in the third quarter valued at approximately $2,011,000. Old West Investment Management LLC bought a new position in shares of Kadmon in the third quarter valued at approximately $169,000. Wells Fargo & Company MN lifted its holdings in shares of Kadmon by 23.2% in the third quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after purchasing an additional 13,923 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in shares of Kadmon in the third quarter valued at approximately $3,685,000. 51.90% of the stock is owned by hedge funds and other institutional investors.

Shares of Kadmon (KDMN) traded down $0.06 on Thursday, hitting $3.58. The stock had a trading volume of 241,846 shares, compared to its average volume of 289,422. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.93.

Kadmon (NYSE:KDMN) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The firm had revenue of $2.28 million during the quarter, compared to the consensus estimate of $5.69 million. During the same period last year, the business earned ($4.24) EPS. Kadmon’s revenue was down 60.0% compared to the same quarter last year. research analysts predict that Kadmon will post -1.61 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of “Hold” by Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/14/kadmon-holdings-inc-kdmn-given-consensus-rating-of-hold-by-brokerages.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.